Characteristic Tofacitinib group, n=72 Control group, n=185 p
Age, years 61 (50-68) 61 (52-71) 0.95
Male gender, n (%) 39 (54.2) 102 (55.1) 0.89
BMI, kg/m2 29.7 (26.9-33.0) 30.8 (26.3-33.9) 0.57
Time from disease onset to enrollment, days 10 (7-12) 8 (6-10) <0.01
Persistent fever, n (%) 60 (83.3) 133 (71.9) 0.08
CRP>50 mg/L, n (%) 60 (83.3) 182 (98.4) <0.01
Comorbidities, n (%)
Hypertension 41 (56.9) 111 (60.0) 0.67
Diabetes 13 (18.1) 40 (21.6) 0.61
Obesity 29/61 (47.5) 77/150 (51.3) 0.65
History of stroke 2 (2.8) 11 (5.9) 0.53
History of myocardial infarction 3 (4.2) 16 (8.6) 0.29
Malignancy 2 (2.8) 7 (3.8) 1.00
COPD 2 (2.8) 7 (3.8) 1.00
Other* 34 (47.2) 91 (49.2) 0.78
Oxygen support at enrollment, n (%)
Nasal oxygen 71 (98.6) 184 (99.5) 0.48
Non-invasive ventilation 1 (1.4) 1 (0.5) 0.48
Oxygen saturation, % 90 (87-92) 90 (88-92) 0.93
Extent of lung involvement on CT, n (%)
0-24% 2 (2.8) 3 (1.6) 0.62
25-49% 37 (51.4) 55 (29.7) <0.01
50-74% 26 (36.1) 105 (56.7) <0.01
≥75 7 (9.7) 17 (9.2) 1.00
Missing data
Body temperature (axillary), °C 38.0 (38.5-38.7) 37.6 (37.2-38.1) <0.01
Blood parameters
White cells, ×109/L 5.9 (4.2-7.5) 6.1 (4.8-8.1) 0.70
Neutrophils, ×109/L 4.1 (2.9-5.6) 4.6 (3.4-6.3) 0.19
Lymphocytes, ×109/L 1.0 (0.7-1.3) 0.9 (0.7-1.3) 0.45
CRP, mg/L 89.4 (62.6-154.2) 106.5 (79.0-148.5) 0.02
LDH, U/L 654.5 (532.5-871.3) 732.0 (566.5-894.0) 0.46
Creatinine, mcmol/L 93.4 (87.0-115.0) 95.5 (84.7-115.9) 0.81
Concomitant therapy, n (%)
Antimalarials 63 (87.5) 173 (93.5) 0.13
Lopinavir-ritonavir 10 (13.9) 80 (43.2) <0.01
Glucocorticoids 31 (43.7) 39 (21.1) <0.01
Azithromycin 54 (75.0) 157 (84.9) 0.07
Other antibiotics 47 (65.3) 145 (78.4) 0.04
Low molecular weight heparins 69 (95.8) 160 (86.5) 0.04